Cardiometabolic & kidney

Albiglutide and atrial fibrillation in patients with Type 2 diabetes and established cardiovascular disease: insights from the Harmony Outcomes trial

Eur J Prev CardiolPublished Secondary analysis of the Harmony Outcomes randomised trial

Authors' conclusion

In patients with Type 2 diabetes, treatment with albiglutide, compared with placebo, reduced the risk of cardiovascular events irrespective of history of AF. Further, albiglutide treatment did not increase AF adverse events but was associated with a trend to a lower rate of AF events during follow-up without reaching statistical significance.

Study context

Population
Patients aged >40 years with T2DM and established CVD8.9% with history of and flutter (AF)
Participants
9,463 patients
Comparison
Albiglutide vs placebo, by history of AF
Primary endpoint
Primary composite MACE endpoint
Follow-up
1.6 years
Methodological detailsmulticentre, event-driven, double-blind, placebo-controlled
  • Multicentre
  • Event-driven
  • Double-blind
  • Placebo-controlled

Primary result

As reported in the abstract

MACE, by baseline history of AF (subgroups)
Albiglutide vs PlaceboAdjusted hazard ratio (CI)
History of AF
0.83(0.58–1.19)
No history of AF
0.77(0.66–0.90)

Further findings

OutcomeaHR (95% CI)P value
MACE, history of AFvs no history of AF · 1.6 years of follow-up12.7 vs. 6.3 events/100 person-years1.41 (1.14–1.74)P = 0.001

Safety

Events

OutcomeAlbiglutidePlaceboHR (CI)P value
AF events during follow-up1081310.82 (0.63–1.06)P = 0.12
AF events during follow-up — Patients with an AF event during follow-up
239 (2.5%)
  • AF events during follow-up: irrespective of baseline history of AF (Pinteraction = 0.92)

Original publication

Albiglutide and atrial fibrillation in patients with Type 2 diabetes and established cardiovascular disease: insights from the Harmony Outcomes trial. Eur J Prev Cardiol. Published 27 November 2024. doi:10.1093/eurjpc/zwae379

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.